https://compepharma.com/story/o-a848e35fc89eb7c8CompePharmaen2026-11-13Medline details repair and replace programme for recalled beds, rails, mattresses and accessorieshttps://compepharma.com/story/c-bc5e9c020181bcf41273CompePharmaen2026-11-13BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6Mhttps://compepharma.com/story/c-ea78be4680dbcaae406fCompePharmaen2026-11-13IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0Mhttps://compepharma.com/story/c-7bac75cd441265042b6dCompePharmaen2026-11-13Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 INDhttps://compepharma.com/story/c-746ec119769afbeff900CompePharmaen2026-11-13IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approachhttps://compepharma.com/story/c-752198cf933dd31cbe30CompePharmaen2026-11-13Imricor starts US launch of NorthStar iMR system after paediatric FDA clearanceshttps://compepharma.com/story/c-0db254b4ba607ba4a8ceCompePharmaen2026-11-13Helus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation riseshttps://compepharma.com/story/c-240bad34c7d3adf3d7f0CompePharmaen2026-11-13Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PHhttps://compepharma.com/story/c-811777c899b2328f0396CompePharmaen2026-11-13IM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israelhttps://compepharma.com/story/c-74d9e16e8d3418c8964dCompePharmaen2026-11-13MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer firsthttps://compepharma.com/story/c-53f4dc62f13b5a8c210bCompePharmaen2026-11-13Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trialhttps://compepharma.com/story/c-63f117ca441190f2bc08CompePharmaen2026-11-13DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensinghttps://compepharma.com/story/c-62d2fccb41f07c07636fCompePharmaen2026-11-13FDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapyhttps://compepharma.com/story/c-3dce2dfc57e64b3f9034CompePharmaen2026-11-13BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLChttps://compepharma.com/story/c-a866513e69da3de43cfaCompePharmaen2026-11-13FDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100https://compepharma.com/story/c-643c892242ede9720cd7CompePharmaen2026-11-13Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027https://compepharma.com/story/c-cc234b08df4c9379a0f6CompePharmaen2026-11-13Cingulate nearly done with manufacturing fixes for ADHD drug CTx-1301 ahead of NDA resubmissionhttps://compepharma.com/story/c-a01468a8d547eb587ac1CompePharmaen2026-11-13Bluejay completes SYMON-II enrolment for Symphony IL-6 sepsis test, eyes 510(k) filing in H1 2027https://compepharma.com/story/c-1555764ceb6e93a65141CompePharmaen2026-11-13CHMP backs Cosentyx for adolescents aged 12+ with moderate-to-severe hidradenitis suppurativahttps://compepharma.com/story/n-a084e76082d9cdfceeb3CompePharmaen2026-11-13Philips recalls Azurion 7 M20 over software faults that can halt imaging or stand movementhttps://compepharma.com/story/c-f3e0716472f742a8c49fCompePharmaen2026-11-13Valneva: 94% of adults still seroresponders five years after single IXCHIQ dosehttps://compepharma.com/story/c-115315367dee320ae6c1CompePharmaen2026-11-13Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patienthttps://compepharma.com/story/c-baf682c3549a12119332CompePharmaen2026-11-13Lifeward Q3 revenue falls 12% as AlterG grows and ReWalk moves to channel partnershttps://compepharma.com/story/c-1de08a8e1012cfa96ffaCompePharmaen2026-11-13GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stagehttps://compepharma.com/story/c-2a3377d79610c37dae39CompePharmaen2026-11-13Medicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filinghttps://compepharma.com/story/c-3125da9dfa5315e8ebfeCompePharmaen2026-11-13FDA lifts ARD-101 clinical hold in Prader-Willi; Aardvark to run open-label trialhttps://compepharma.com/story/c-225c80f18fc349ac959eCompePharmaen2026-11-13MetaVia details DA-1726 interim data and vanoglipel MASH plans in investor deckhttps://compepharma.com/story/c-27113b583630e4846173CompePharmaen2026-11-13Fortress Biotech Q3 revenue rises 9% to $19.2M as Oaktree facility is repaidhttps://compepharma.com/story/c-c438ff045d1b6a2f48a1CompePharmaen2026-11-13Benitec: all treated OPMD patients responded to BB-301; pivotal trial planned for mid-2027https://compepharma.com/story/c-1b10546a3d2fe5bddd6aCompePharmaen2026-11-13TuHURA wins FDA IND clearance for VISTA antibody TBS-2025 in relapsed AMLhttps://compepharma.com/story/c-71aedd335b6551140dacCompePharmaen2026-11-13Milestone cuts costs by about 30% as CARDAMYST posts $1.0M third-quarter saleshttps://compepharma.com/story/c-ed0b021ed68bb9670d47CompePharmaen2026-11-13Biofrontera wins FDA nod for Ameluz in superficial BCC as Q3 revenue rises 30%https://compepharma.com/story/c-cf21e4b34b6b724104a6CompePharmaen2026-11-13CHMP backs Roche's Gazyvaro as add-on therapy for autoantibody-positive lupushttps://compepharma.com/story/c-7c54272a35f63d3b90daCompePharmaen2026-11-13CHMP recommends Roche's Gazyvaro as add-on therapy for autoantibody-positive lupushttps://compepharma.com/story/c-51c6d6972259e3278606CompePharmaen2026-11-13Quantum BioPharma reports Q3 equity up 91% as Lucid-MS Phase 2 start-up advanceshttps://compepharma.com/story/c-648dd786dc5a5b6c5acbCompePharmaen2026-11-13Grown Rogue posts $11.0M Q3 revenue, books $8.9M net loss on Illinois dealhttps://compepharma.com/story/c-d906fda6c67e307c7010CompePharmaen2026-11-13Bavarian Nordic Q3 revenue flat at DKK 1,805m as Travel Health grows 22%https://compepharma.com/story/o-94da0395c997918eCompePharmaen2026-11-13Florida man pleads guilty to $42M Medicare fraud over braces and cancer genetic testshttps://compepharma.com/insights/2026-11-15-zymeworks-250m-ziihera-milestone-lifts-q3-and-guidance-but-the-base-business-isCompePharmaen2026-11-15Zymeworks' $250M Ziihera milestone lifts Q3 and guidance, but the base business is still being builthttps://compepharma.com/insights/2026-11-14-view-revenue-is-not-the-scoreboard-earnings-season-rewards-what-each-dollar-is-worthCompePharmaen2026-11-14Revenue is not the scoreboard: earnings season rewards what each dollar is worthhttps://compepharma.com/insights/2026-11-14-biocryst-s-q3-caremed-inventory-build-flatters-orladeyo-as-profits-roughly-doublCompePharmaen2026-11-14BioCryst's Q3: CareMed inventory build flatters ORLADEYO as profits roughly double and guidance riseshttps://compepharma.com/insights/2026-11-14-cormedix-s-heron-asset-buy-adds-four-marketed-drugs-and-about-150m-in-revenueCompePharmaen2026-11-14CorMedix's Heron Asset Buy Adds Four Marketed Drugs and About $150M in Revenuehttps://compepharma.com/insights/2026-11-14-view-compepharma-view-strong-quarters-narrow-foundationsCompePharmaen2026-11-14CompePharma View: Strong quarters, narrow foundationshttps://compepharma.com/insights/2026-11-14-richter-gives-lilly-estetrol-combination-rights-keeping-a-us-option-on-fylrevyCompePharmaen2026-11-14Richter Gives Lilly Estetrol Combination Rights, Keeping a US Option on FYLREVYhttps://compepharma.com/insights/2026-11-14-transmedics-q3-revenue-up-41-but-opex-growth-squeezes-margins-and-epsCompePharmaen2026-11-14TransMedics' Q3: Revenue up 41%, but opex growth squeezes margins and EPShttps://compepharma.com/insights/2026-11-14-xenetic-s-all-stock-santersus-deal-shows-how-small-cap-biotechs-are-trading-equiCompePharmaen2026-11-14Xenetic's all-stock Santersus deal shows how small-cap biotechs are trading equity for assetshttps://compepharma.com/insights/2026-11-14-view-the-second-act-is-where-this-quarter-s-money-was-madeCompePharmaen2026-11-14The second act is where this quarter's money was madehttps://compepharma.com/insights/2026-11-14-macrogenics-funds-mgc026-through-2028-by-selling-assets-and-royalties-not-equityCompePharmaen2026-11-14MacroGenics Funds MGC026 Through 2028 by Selling Assets and Royalties, Not Equityhttps://compepharma.com/insights/2026-11-14-united-therapeutics-q3-tyvaso-dpi-lifts-sales-4-but-a-130m-r-d-charge-cuts-net-iCompePharmaen2026-11-14United Therapeutics Q3: Tyvaso DPI lifts sales 4%, but a $130M R&D charge cuts net income 24%https://compepharma.com/insights/2026-11-13-view-a-fee-schedule-rate-is-not-a-durable-price-coverage-is-the-real-assetCompePharmaen2026-11-13A fee schedule rate is not a durable price: coverage is the real assethttps://compepharma.com/insights/2026-11-13-collegium-s-q3-adhd-growth-and-azstarys-offset-a-pain-decline-but-profit-fallsCompePharmaen2026-11-13Collegium's Q3: ADHD growth and AZSTARYS offset a pain decline, but profit fallshttps://compepharma.com/insights/2026-11-13-cma-narrows-akzonobel-axalta-concerns-to-uk-refinish-testing-a-one-remedy-playboCompePharmaen2026-11-13CMA narrows AkzoNobel-Axalta concerns to UK refinish, testing a one-remedy playbookhttps://compepharma.com/insights/2026-11-13-view-plan-the-exit-before-the-readout-strategic-alternatives-shouldn-t-start-after-aCompePharmaen2026-11-13Plan the exit before the readout: strategic alternatives shouldn't start after a misshttps://compepharma.com/insights/2026-11-13-theriva-s-350-000-syn-004-sale-shows-how-small-biotechs-are-pruning-to-a-singleCompePharmaen2026-11-13Theriva's $350,000 SYN-004 sale shows how small biotechs are pruning to a single bethttps://compepharma.com/insights/2026-11-13-irhythm-s-q3-volume-led-growth-and-23-1-adjusted-ebitda-margin-masked-by-a-49-8mCompePharmaen2026-11-13iRhythm's Q3: Volume-led growth and 23.1% adjusted EBITDA margin, masked by a $49.8M litigation chargehttps://compepharma.com/insights/2026-11-13-merck-kgaa-s-pending-silence-deal-lands-as-divesiran-data-de-risk-an-rnai-assetCompePharmaen2026-11-13Merck KGaA's pending Silence deal lands as divesiran data de-risk an RNAi assethttps://compepharma.com/insights/2026-11-13-view-evidence-or-revenue-biotech-s-middle-ground-is-where-deals-go-to-dieCompePharmaen2026-11-13Evidence or revenue: biotech's middle ground is where deals go to diehttps://compepharma.com/insights/2026-11-13-longeveron-s-elpis-ii-miss-opens-a-sale-or-merge-review-as-biotech-deal-value-spCompePharmaen2026-11-13Longeveron's ELPIS II miss opens a sale-or-merge review as biotech deal value splitshttps://compepharma.com/insights/2026-11-13-obsidian-s-first-quarter-as-a-public-company-324-4m-cash-a-widening-loss-and-a-2CompePharmaen2026-11-13Obsidian's first quarter as a public company: $324.4M cash, a widening loss and a 2027 readout